Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Research and Markets: Novartis: Divestments, Mergers, and Acquisitions Create a Diverse Healthcare Company

Research and Markets
Posted on: 01 Feb 13

Research and Markets (http://www.researchandmarkets.com/research/mfrphs/novartis) has announced the addition of the "Novartis: Divestments, Mergers, and Acquisitions Create a Diverse Healthcare Company" report to their offering.

In 1996 Ciba-Geigy merged with Sandoz to form Novartis. In 1997, 2000, 2006, and 2007 it divested its specialty chemicals, agribusiness, nutrition, and medical nutrition and baby foods businesses, respectively. Novartis has also made acquisitions to strengthen its position in the healthcare market, and now generates 100% of revenues from healthcare, and operates through five diverse segments.

Features and benefits

- MarketLine Case Studies describe topics such as innovative products, business models, and significant company acquisitions.

- Fact-based and presented in an accessible style, they explain the rationale of commercial decisions and illustrate wider market and economic trends.

Highlights

The global population is growing older, and Novartis Pharmaceuticals provides products aimed at high- and middle-income countries, where a higher proportion of the population reaches old age. Novartis Pharmaceuticals' product lines reflect the most common causes of death in these countries.

While vaccines are estimated to save the lives of over 3 million people annually, the World Health Organization (WHO) estimates that over 3 million people die annually due to a lack of access to vaccines. The Vaccines and Diagnostics division has a product development portfolio of 15 potential products in various stages of clinical development.

The Consumer Health segment represents only 8% of sales. Despite this, the segment is important in providing stable growth to offset fluctuations in the less stable segments of Sandoz and Pharmaceuticals.

Your key questions answered

- How has Novartis changed to generate 100% of its revenues from healthcare sales, rather than the 45% that healthcare sales contributed in 1996?

- What mergers, acquisitions, and divestments has Novartis made, and how have these affected the company?

- Which areas of healthcare is Novartis present in?

Key Topics Covered:

- Overview

- Novartis's Origins Trace Back To Three Companies

- Conclusion

- Appendix

For more information visit http://www.researchandmarkets.com/research/mfrphs/novartis

Business Wire
http://www.businesswire.com/

Last updated on: 01/02/2013

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.